2021 Generics and Biosimilars Outlook
This article first appeared in Chain Drug Review on January 5, 2021 as Pharmacy Outlook: Dan Leonard.
Helen Knows She Can Rely on Biosimilars
Diagnosed in her late twenties with incurable stage four non-Hodgkin lymphoma, Helen, now 41 and a wife and mother of two in Florida, knows she can rely on biosimilars to help when needed, so she can live her life to the fullest.
Top 10 Ways to Commemorate 10 Years of Biosimilars in the U.S.
U.S. biosimilar medicines are 10 years old this year. It’s been an amazing journey so far, and we see great promise and opportunity ahead, with greater access and lower prices for patients with cancer, Crohn’s disease, rheumatoid arthritis and other conditions. Here are 10 ways to mark this auspicious anniversary:
10. Learn more about the 10th anniversary of the Biologics Price Competition and Innovation Act (BPCIA) at www.b10similars.org.
Jeni Got Her Life Back, Thanks to a Biosimilar
In 2019, Jeni Doerr finally received a diagnosis for her recent illnesses – pancolitis. Doerr, 35, from Newhall, CA, is featured in AAM’s recently released 2020 Generic Drug & Biosimilars Access & Savings in the U.S. report.
Jeni's Story — Savings from Biosimilar Medicines
Jeni Doerr, 35, has recently gone back to school to become a medical coder and when she is not online learning, she is outside enjoying everything California has to offer through hiking, rock climbing and mountain biking with her dog Sally. Jeni takes the biosimilar Inflectra for her pancolitis.
"If I'd known I could be on a biosimilar, I'd have done it immediately." —Jeni, Santa Clarita, CA
Celebrate a decade of biosimilar savings at https://b10similars.org/.
Christine Simmon: Policy and Biosimilars Sessions at the GRx+Biosims 2020 Virtual Conference
GRx+Biosims is going virtual, join us from around the globe on November 9-11, 2020. You can look forward to the same impactful and news making content you have experienced at past GRx+Biosims events. If you care about generic and biosimilar development, the regulatory process and approvals, and the evolving policy landscape, this is the one conference you cannot afford to miss.
We’ll have:
AAM Commends Introduction of the Increasing Access to Biosimilars Act
WASHINGTON, DC (July 2, 2020) — AAM and its Biosimilars Council commend Senators Cornyn and Bennet for introduction of the Increasing Access to Biosimilars Act. This bipartisan proposal is based on a simple idea – that Medicare policies should encourage the use of the most effective, lowest-cost medicine. Biosimilars consistently deliver savings compared to high-priced brand biologics. We encourage Congress and the Administration to quickly implement this policy and deliver savings to America’s patients and taxpayers.
AAM Files Amicus Brief Supporting the BPCIA
WASHINGTON, DC (May 14, 2020) — The Association for Accessible Medicines (AAM) has filed an amicus brief in the latest constitutional challenge to the Affordable Care Act (ACA), arguing that even if the individual mandate of the ACA is deemed unconstitutional, the biosimilars pathway (BPCIA) should survive.
USMCA: Nothing to See Here (Infographic)
Brand-name drug companies claim that without USMCA, there's no market for biologics in Mexico. But, the world's largest pharmaceutical companies launched their top-selling biologics in Mexico. Learn more in this infographic:
Myths vs. Facts of Biologic Market Exclusivity in Mexico — #FixUSMCA
The pharmaceutical provisions included in the negotiated text of the U.S.-Mexico-Canada Agreement will do many things. But creating a market for biologics in Mexico is not one of them. Why? Because pharmaceutical companies have been selling original biologics in Mexico since before 2001.